Drug General Information
Drug ID
D07AEC
Former ID
DNC010616
Drug Name
RESCOVITINE
Drug Type
Small molecular drug
Indication Discovery agent Investigative [530612]
Structure
Download
2D MOL

3D MOL

Formula
C19H28N6O
Canonical SMILES
CCC(CO)NC1=NC2=C(C(=N1)NCC3=CC=CC=C3)NCN2C(C)C
InChI
1S/C19H28N6O/c1-4-15(11-26)22-19-23-17(20-10-14-8-6-5-7-9-14)16-18(24-19)25(12-21-16)13(2)3/h5-9,13,15,21,26H,4,10-12H2,1-3H3,(H2,20,22,23,24)/t15-/m1/s1
InChIKey
RMSINZVFNDWCCK-OAHLLOKOSA-N
PubChem Compound ID
Target and Pathway
Target(s) Cyclin-A2 Target Info Inhibitor [530612]
Cell division protein kinase 2 Target Info Inhibitor [530612]
KEGG Pathway DNA replication
Base excision repair
Nucleotide excision repair
Mismatch repair
Cell cycle
Hepatitis B
HTLV-I infectionhsa04068:FoxO signaling pathway
Oocyte meiosis
p53 signaling pathway
PI3K-Akt signaling pathway
Progesterone-mediated oocyte maturation
Measles
Herpes simplex infection
Epstein-Barr virus infection
Pathways in cancer
Viral carcinogenesis
Prostate cancer
Small cell lung cancer
NetPath Pathway TCR Signaling Pathway
PANTHER Pathway p53 pathway
p53 pathway feedback loops 2
Pathway Interaction Database Regulation of nuclear SMAD2/3 signaling
Signaling events mediated by PRL
p73 transcription factor network
E2F transcription factor network
ATR signaling pathway
mTOR signaling pathway
IL2-mediated signaling events
FoxO family signaling
FOXM1 transcription factor network
BARD1 signaling events
p53 pathway
Regulation of retinoblastoma protein
PathWhiz Pathway Nucleotide Excision Repair
Reactome E2F mediated regulation of DNA replication
G0 and Early G1
Cdc20:Phospho-APC/C mediated degradation of Cyclin A
Regulation of APC/C activators between G1/S and early anaphase
SCF(Skp2)-mediated degradation of p27/p21
Senescence-Associated Secretory Phenotype (SASP)
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
HDR through Homologous Recombination (HRR)
Processing of DNA double-strand break ends
Dual Incision in GG-NER
Dual incision in TC-NER
Gap-filling DNA repair synthesis and ligation in TC-NER
G2 Phase
Orc1 removal from chromatin
G1/S-Specific Transcription
Cyclin A/B1 associated events during G2/M transition
Cyclin A:Cdk2-associated events at S phase entryR-HSA-1538133:G0 and Early G1
Activation of ATR in response to replication stress
DNA Damage/Telomere Stress Induced Senescence
Cyclin E associated events during G1/S transition
p53-Dependent G1 DNA Damage Response
Cyclin A:Cdk2-associated events at S phase entry
Meiotic recombination
Factors involved in megakaryocyte development and platelet production
WikiPathways Senescence and Autophagy in Cancer
Mismatch repair
DNA Replication
G1 to S cell cycle control
EGF/EGFR Signaling Pathway
S Phase
Nifedipine Activity
Primary Focal Segmental Glomerulosclerosis FSGS
Retinoblastoma (RB) in Cancer
Integrated Pancreatic Cancer Pathway
Nucleotide Excision Repair
Telomere Maintenance
Synthesis of DNA
Mitotic G1-G1/S phases
Cell Cycle
Base Excision RepairWP707:DNA Damage Response
ID signaling pathway
M/G1 Transition
Meiotic Recombination
Aryl Hydrocarbon Receptor
ATM Signaling Pathway
Spinal Cord Injury
Oncostatin M Signaling Pathway
Prostate Cancer
Signaling Pathways in Glioblastoma
TSH signaling pathway
Integrated Breast Cancer Pathway
Integrated Cancer pathway
Regulation of DNA replication
Mitotic G2-G2/M phases
Factors involved in megakaryocyte development and platelet production
APC/C-mediated degradation of cell cycle proteins
Cell Cycle Checkpoints
miRNA Regulation of DNA Damage Response
References
Ref 530612Eur J Med Chem. 2010 Mar;45(3):1158-66. Epub 2009 Dec 21.Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors.
Ref 530612Eur J Med Chem. 2010 Mar;45(3):1158-66. Epub 2009 Dec 21.Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.